Sellas Life Sciences: A $150 Million Placement, a 41% Survival Benefit, and the Dilution That Comes With Both
Published on 11/20/2026 at 17:30 | Editorial boerse-global.deMaxim Group analyst Jason McCarthy lifted his price target on Sellas Life Sciences from $30 to $40 on Tuesday, keeping his Buy rating intact. The upgrade landed the same day the company reported that its Phase III REGAL trial had hit its primary endpoint on overall survival — and one day before Sellas went to market with a fresh equity raise. Read together, the three events tell a single story about how clinical data gets converted into capital, and what that capital costs existing holders.
The raise, in plain numbers
Sellas priced its public offering at $13.00 per share on Wednesday, placing roughly 11.5 million newly issued shares — 11,538,462 to be exact — for expected gross proceeds of $150.0 million before fees and expenses. The prospectus puts net proceeds at approximately $140.6 million. The underwriting banks hold a 30-day option on up to 1,730,769 additional shares; if exercised in full, gross proceeds would climb to about $161.8 million and net proceeds to roughly $161.8 million. Closing was expected today, subject to customary conditions.
Two distinctions matter here. The gross figure is not the number that reaches the balance sheet — discounts, commissions and costs come out first, which is why the net estimate sits about $9.4 million lower. And the greenshoe is an option, not committed capital; treating it as certain would be a mistake. Every extra dollar from that option arrives attached to more shares. More financial room and a larger share count are two halves of the same decision.
The placement does not stand alone. Sellas reported $134.7 million in cash and cash equivalents as of September 30, 2026, so the new money builds on an already disclosed cash position rather than rescuing a stretched balance sheet.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
What the REGAL data actually showed
The financing follows Tuesday's REGAL readout, and the trial numbers are the reason the capital was available at all. Galinpepimut-S met the primary endpoint of overall survival in acute myeloid leukemia. Median overall survival came in at 24.0 months on the treatment arm versus 14.7 months on best available care, a hazard ratio of 0.59. Per the company, the risk of death fell 41% relative to best available treatment, with a p-value of 0.035.
Those figures are the medical foundation for everything that follows — but a survival benefit and an approval strategy answer different questions. Sellas intends to discuss an accelerated submission pathway with the US Food and Drug Administration and is preparing a biologics license application, or BLA, for the first half of 2027. That timeline is a plan, not a regulatory decision, and it is the next real test of the story.
Where the two threads meet
The temptation is to read Sellas purely as a clinical-success story, or purely as a financing event. Neither framing holds up alone. The REGAL result is what made a $150 million placement possible on reasonable terms; the placement is what funds the work of turning that result into a filing. McCarthy's move to $40 captures the first half of that equation. The share count captures the second.
What investors are left weighing is the combination: the strength of the clinical signal, the capital that is actually in hand once the closing conditions are satisfied, and execution against the regulatory plan. A positive headline is a starting point. The durability of the company's prospects depends on how those three pieces fit together.
Ad
Sellas Life Sciences Stock: New Analysis - 20 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
